ENDV Stock - Endonovo Therapeutics, Inc.
Unlock GoAI Insights for ENDV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10,043 | $140,242 | $135,355 | $73,105 | $165,796 |
| Gross Profit | $-615,198 | $-514,510 | $125,365 | $58,120 | $100,427 |
| Gross Margin | -6125.6% | -366.9% | 92.6% | 79.5% | 60.6% |
| Operating Income | $-1,559,933 | $-2,919,444 | $-3,264,340 | $-2,226,547 | $-2,912,198 |
| Net Income | $-2,797,297 | $6.92M | $-18,474,835 | $-3,104,894 | $-395,584 |
| Net Margin | -27853.2% | 4937.6% | -13649.2% | -4247.2% | -238.6% |
| EPS | $-0.01 | $0.03 | $-0.13 | $-0.05 | $-0.03 |
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
Visit WebsiteEarnings History & Surprises
ENDVEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | — | — | — |
Q3 2025 | Aug 14, 2025 | — | — | — | — |
Q1 2025 | Mar 31, 2025 | — | $-0.00 | — | — |
Q4 2024 | Dec 31, 2024 | — | $-0.00 | — | — |
Q4 2024 | Nov 12, 2024 | — | $0.00 | — | — |
Q3 2024 | Aug 22, 2024 | — | $-0.00 | — | — |
Q1 2024 | Mar 30, 2024 | — | $-0.00 | — | — |
Q4 2023 | Dec 30, 2023 | — | $-0.01 | — | — |
Q4 2023 | Dec 28, 2023 | — | $-0.00 | — | — |
Q3 2023 | Aug 21, 2023 | — | $-0.01 | — | — |
Q2 2023 | May 22, 2023 | — | $0.00 | — | — |
Q2 2023 | Apr 17, 2023 | — | $-0.05 | — | — |
Q4 2022 | Nov 21, 2022 | — | $-0.00 | — | — |
Q3 2022 | Aug 22, 2022 | — | $-0.02 | — | — |
Q2 2022 | May 19, 2022 | — | $-0.03 | — | — |
Q2 2022 | Apr 13, 2022 | — | $0.03 | — | — |
Q4 2021 | Nov 19, 2021 | — | $-0.02 | — | — |
Q3 2021 | Aug 23, 2021 | — | $-0.02 | — | — |
Q2 2021 | May 24, 2021 | — | $-0.06 | — | — |
Q2 2021 | Apr 13, 2021 | — | $-0.13 | — | — |
Latest News
Frequently Asked Questions about ENDV
What is ENDV's current stock price?
What is the analyst price target for ENDV?
What sector is Endonovo Therapeutics, Inc. in?
What is ENDV's market cap?
Does ENDV pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ENDV for comparison